Juventas Therapeutics

Juventas Therapeutics

Early Stage Partners participated in the Series A early stage venture capital investment in Juventas Therapeutics, which is developing Stromal Derived Factor, or SDF-1, to repair damage to heart and other tissue. SDF-1 is a naturally occurring universal recruiter of a body's own stem cells to areas of damaged tissue. Juventas is demonstrating that the application of SDF-1 to injured tissue, long after the body's own repair mechanism has ceased producing SDF-1, can regenerate tissue by promoting new blood vessel formation and preventing ongoing cell death.


Recent Juventas News

Juventas Therapeutics Closes $22.2 Million Series C Venture Capital Round
Juventas Therapeutics Raises $12 Million Early Stage Venture Capital Round
Juventas Founder Marc Penn Explains Juventas' Therapy on Television News
Juventas Cleared to Being Phase II Clinical Trials For Critical Limb Ischemia
Juventas Successfully Completes Phase I Trial Of Its Lead Compound



Find Out More About ESP

Staff Photo

Mike Bunker serves as an observer on the board of Juventas Therapeutics.